A study to test Aumolertinib in European participants with genetically linked advanced Lung Cancer

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519618-29-00

Acronym

HS-10296-108

Enrollment

Registered

2025-03-27

Start date

2025-04-08

Completion date

2025-07-18

Last updated

2025-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations

None listed

Sex/Gender

All

Age

18 Years to No maximum

Bulgaria

None listed

Source: EU CTIS · Data processed: Feb 4, 2026